Suppr超能文献

1994 - 2000年瑞士海洛因辅助治疗中的死亡率

Mortality in heroin-assisted treatment in Switzerland 1994-2000.

作者信息

Rehm Jürgen, Frick Ulrich, Hartwig Christina, Gutzwiller Felix, Gschwend Patrick, Uchtenhagen Ambros

机构信息

Addiction Research Institute, Konradstr. 32, CH 8031 Zurich, Switzerland.

出版信息

Drug Alcohol Depend. 2005 Aug 1;79(2):137-43. doi: 10.1016/j.drugalcdep.2005.01.005. Epub 2005 Feb 26.

Abstract

BACKGROUND

A major goal of heroin-assisted treatment in Switzerland has been to reduce the drug-related mortality of heroin users. Therefore, a continuous monitoring of deaths under treatment is essential.

AIMS

To assess mortality of participants in heroin-assisted treatment in Switzerland over a 7-year period from 1994 to 2000, and to compare this mortality to the general population and to other populations of opioid users, as reported in the literature.

METHOD

Estimation of person years under heroin-assisted treatment from the complete case registry of heroin-assisted treatment in Switzerland. Estimation of standardized mortality ratios comparing the population in treatment to the Swiss population (standardized to the year 2000).

RESULTS

Over the 7-year period, the crude death rate of patients in heroin-assisted treatment, and including one month after discharge from treatment, was 1% per year. The standardized mortality ratio for the entire observation period was 9.7 (95% C.I. 7.3-12.8), with females having higher standardized mortality ratios (SMR 17.2) than males (SMR 8.4). There was no clear time trend.

CONCLUSION

Mortality in heroin-assisted treatment was low compared to the mortality rate of Swiss opioid users 1990s (estimated to be between 2.5 and 3%). It was also low compared to mortality rates of opioid users in other maintenance treatments in other countries as reported in the literature. The SMR was also lower than that reported in the only meta-analysis in the literature: 13.2 (95% C.I. 12.3-14.1). The low mortality rate is all the more noteworthy as heroin-assisted treatment in Switzerland included only refractory opioid addicts with existing severe somatic and/or mental problems.

DECLARATION OF INTEREST

No conflicts of interest declared.

摘要

背景

瑞士海洛因辅助治疗的一个主要目标是降低海洛因使用者与毒品相关的死亡率。因此,持续监测治疗期间的死亡情况至关重要。

目的

评估1994年至2000年瑞士海洛因辅助治疗参与者在7年期间的死亡率,并将该死亡率与一般人群以及文献中报道的其他阿片类药物使用者群体进行比较。

方法

根据瑞士海洛因辅助治疗的完整病例登记册估算接受海洛因辅助治疗的人年数。估算标准化死亡率比,将治疗人群与瑞士人群(标准化至2000年)进行比较。

结果

在这7年期间,接受海洛因辅助治疗的患者(包括出院后一个月)的粗死亡率为每年1%。整个观察期的标准化死亡率比为9.7(95%置信区间7.3 - 12.8),女性的标准化死亡率比(SMR 17.2)高于男性(SMR 8.4)。没有明显的时间趋势。

结论

与20世纪90年代瑞士阿片类药物使用者的死亡率(估计在2.5%至3%之间)相比,海洛因辅助治疗中的死亡率较低。与文献中报道的其他国家其他维持治疗中的阿片类药物使用者死亡率相比也较低。标准化死亡率比也低于文献中唯一的荟萃分析所报告的:13.2(95%置信区间12.3 - 14.1)。鉴于瑞士的海洛因辅助治疗仅包括患有严重躯体和/或精神问题的难治性阿片类成瘾者,低死亡率就更值得注意了。

利益声明

未声明利益冲突。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验